Document is current
Any future updates will be listed below
-
Authors
Shirasawa, Masayuki
Fukui, Tomoya
Kusuhara, Seiichiro
Hiyoshi, Yasuhiro
Nakahara, Yoshiro
Nishinarita, Noriko
Igawa, Satoshi
Naoki, Katsuhiko
- License Information
-
More Information
Article History
Received: 29 March 2018
Accepted: 11 February 2019
First Online: 20 February 2019
Ethics approval and consent to participate
: The retrospective study was approved by the Kitasato University Medical Ethics Organization (B17–253), which waived the requirement for patients’ informed consent.
: Not applicable
: MS has no competing interest. TF has received lecture fee from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd.; and honoraria from Pfizer Japan Inc. SK has no competing interest. YN has received honoraria from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Co. Ltd., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd.; and research founding from SRL Inc.SI has received lecture fee from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd. and Taiho Pharmaceutical Co. Ltd.; and research funding from Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd. and Nippon Kayaku Co. Ltd.KN has received lecture fee from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Co. Ltd., Mochida Pharmaceutical Co. Ltd., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., Shionogi & Co. Ltd. and Taiho Pharmaceutical Co. Ltd.All remaining authors have declared no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
